Managing weight gain as a side effect of antidepressant therapy

Cleveland Clinic Journal of Medicine

Volumn 70, Issue 7, 2003, Pages 614-623

  Deshmukh, Rashmi ^a   Franco, Kathleen ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; CITALOPRAM; DESIPRAMINE; DOXEPIN; FAMOTIDINE; FLUOXETINE; IMIPRAMINE; LIOTHYRONINE; METHYLPHENIDATE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NALTREXONE; NEFAZODONE; NORTRIPTYLINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; ZIMELDINE;

ARTICLE; BODY WEIGHT DISORDER; CLINICAL TRIAL; DEPRESSION; DOCTOR PATIENT RELATION; DRUG MECHANISM; HUMAN; OBESITY; PATIENT COMPLIANCE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0042591732     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.70.7.614     Document Type: Article

References (37)

1. Janicak PG, Davis JM, Preskorn SH, Ayd Fj Jr. Principles and Practice of Psychopharmacology. Baltimore: Williams & Wilkins, 1997:219-273.
2. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2001; 61(suppl 11):37-41.
3. Kaplan HI, Sadock BJ. Mood disorders. In: Kaplan and Sadock's Synopsis of Psychiatry: behavioral sciences, clinical psychiatry. 8th ed. Baltimore: Williams & Wilkins, 1998:524-580.
4. Diagnostic and Statistical Manual of Mental Disorders, 4th ed (DSM-IV). Washington DC: American Psychiatric Association Press.
5. Malhotra S, McElroy SL. Medical management of obesity associated with mental disorders. J Clin Psychiatry 2002; 63:(suppl 4):24-32.
6. Rabkin J, Quitkin F, Harrison W, Tricamo E, McGrath P. Adverse reactions to monoamine oxidase inhibitors. Part 1: a comparative study. J Clin Psychopharmacol 1984; 4:270-278.
7. Cantu TG, Korek JS. Monoamine oxidase inhibitors and weight gain. Drug Intell Clin Pharm 1988; 22:755-759.
8. Sussman N, Ginsberg D. Effects of psychotropic drugs on weight. Psychiatr Ann 1999; 29:580-594.
9. Pijl H, Meinders AE. Bodyweight change as an adverse effect of drug treatment: mechanisms and management. Drug Saf 1996; 14:329-342.
10. Fernstrom MH, Kupfer DJ. Antidepressant-induced weight gain: a comparison study of four medications. Psychiatry Res 1988; 26:265-271.
11. Frank E, Kupfer DJ, Bulik CM, Levenson JA. Imipramine and weight gain during the treatment of recurrent depression. J Affect Disord 1990; 20:165-172.
12. Rigler SK, Webb MJ, Redford L, Brown EF, Zhou J, Wallace D. Weight outcomes among antidepressant users in nursing facilities. J Am Geriatr Soc 2001; 49:49-55.
13. Benazzi F. Weight gain in depression remitted with antidepressants: pharmacological or recovery effect? Psychother Psychosom 1998; 67:271-274.
14. Bouwer CD, Harvey BH. Phasic craving for carbohydrate observed with citalopram. Int Clin Psychopharmacol 1996; 11:273-278.
15. Michelson D, Amsterdam JD, Quitkin FM, et al. Changes in weight during a 1-year trial of fluoxetine. Am J Psychiatry 1999; 156:1170-1176.
16. Croft H, Settle E Jr, Houser T, Batey SR, Donahue RM, Ascher JA. A placebo-controlled comparison of the antidepressant efficacy and effects of sexual functioning of sustained release bupropion and sertraline. Clin Ther 1999; 21:643-658.
17. Mackle M, Kocsis J. Effects on body weight of the SSRI citalopram. Presented at the 37th annual meeting of the American College of Neuropsychopharmacology; Dec 14-18, 1998: Las Croabas, Puerto Rico.
18. Sussman N, Ginsberg D. Rethinking side effects of the selective serotonin reuptake inhibitors: sexual dysfunction and weight gain. Psychiatr Ann 1998; 28:89-97.
19. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 2000; 157(suppl 4):1-45.
20. Wade A, Overo KF, Lemming O, et al. Weight monitoring during two long term trials of citalopram. Presented at the 12th Congress of the European College of Neuropsychopharmacology; Sept 21-25, 1999; London, England.
21. Hochstrasser B, Isaksen PM. Prophylactic effect of citalopram in unipolar, recurrent depression: placebo-controlled study of maintenance therapy. Br J Psychiatry 2001; 178:304-310.
22. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC. Fluoxetine vs sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000; 61:863-867.
23. Agren H, Aberg-Wistedt A, Akerblad AC, et al. Sertraline vs paroxetine in major depression: a multicenter double blind 24 week comparison. Presented at the 152nd annual meeting of the APA; May 1999, Toronto, Ontario, Canada.
24. Fieger AD, Bielski RJ, Bremner J, et al. Double-blind, placebo-substitution study of nefazodone in the prevention of relapse during continuation treatment of outpatients with major depression. Int Clin Psychopharmacol 1999; 14:19-28.
25. Sussman N, Ginsberg DL, Bikoff J. Effects of nefazodone on body weight: a pooled analysis of SSRI and imipramine controlled trials. J Clin Psychiatry 2001; 62:256-260.
26. Weisler RH, Johnston JA, Lineberry CG, Samara B, Branconnier RJ, Billow AA. Comparison of bupropion and trazodone for the treatment of major depression. J Clin Psychopharmacol 1994; 14:170-179.
27. Feighner J, Hendrickson G, Miller L, Stern W. Double-blind comparison of doxepin versus bupropion in outpatients with major depressive disorder. J Clin Psychopharmacol 1986; 6:27-32.
28. Chouinard G. Bupropion and amitriptyline in the treatment of depressed patients. J Clin Psychiatry 1983; 44:121-129.
29. Weihs K, Houser T, Batey S, et al. Long-term treatment of depression with sustained release bupropion. Presented at the 152nd annual meeting of the American Psychiatric Association; May 2000; Chicago, II.
30. Goodnick PJ, Kremer C. Weight gain during mirtazapine therapy. Prim Psychiatry 1998, 3:103-108.
31. Smith WT, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990; 26:191-196.
32. Montgomery SA, Reimitz PE, Zivkov M. Mirtazapine versus amitriptyline in the long-term treatment of depression: a double blind placebo-controlled study. Int Clin Psychopharmacol 1998; 3:103-108.
33. Guelfi JD, Ansseau M, Timmerman L, Korsgaard S. Mirtazapine vs venlafaxine in hospitalized severely depressed patients with melancholic features. Mirtazapine-Venlafaxine Study Group. J Clin Psychopharmacol 2001; 21:425-431.
34. Stahl SM. Psychopharmacology of antidepressants. London, UK: Dunitz 1998.
35. Silverstone PH, Ravindran A. Once daily venlafaxine extended release compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group. J Clin Psychiatry 1999; 60:22-28.
36. Zajecka JM. Clinical issues in long term treatment with antidepressants. J Clin Psychiatry 2000; 61(suppl 2):20-25.
37. Masand PS. Weight gain associated with psychotropic drugs. Review. Expert Opinion on Pharmacotherapy 2000; 1:377-389.